Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591

医学 前列腺癌 内科学 紫杉烷 肿瘤科 癌症 不利影响 谷氨酸羧肽酶Ⅱ 泌尿科 乳腺癌
作者
Scott T. Tagawa,Charlene Thomas,Oliver Sartor,Michael Sun,Judith Stangl‐Kremser,Mahelia Bissassar,Shankar Vallabhajosula,Sandra Huicochea Castellanos,Jones T. Nauseef,Cora N. Sternberg,Ana M. Molina,Karla V. Ballman,David M. Nanus,Joseph R. Osborne,Neil H. Bander
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (7): 842-851 被引量:67
标识
DOI:10.1200/jco.23.00573
摘要

PURPOSE Novel therapies are needed to extend survival in metastatic castration-resistant prostate cancer (mCRPC). Prostate-specific membrane antigen (PSMA), a cell surface antigen overexpressed in PC, provides a validated target. This dose-escalation study investigated the safety, efficacy, maximum tolerated dose (MTD), and recommended phase II dose (RP2D) for 225 Ac-J591, anti-PSMA monoclonal antibody J591 radiolabeled with the alpha emitter actinium-225. METHODS Following investigational new drug-enabling preclinical studies, we enrolled patients with progressive mCRPC that was refractory to or who refused standard treatment options (including androgen receptor pathway inhibitor and had received or been deemed ineligible for taxane chemotherapy). No selection for PSMA was performed. Patients received a single dose of 225 Ac-J591 at one of seven dose-escalation levels followed by expansion at the highest dose. Primary end point of dose-escalation cohort was determination of dose-limiting toxicity (DLT) and RP2D. RESULTS Radiochemistry and animal studies were favorable. Thirty-two patients received 225 Ac-J591 in an accelerated dose-escalation design (22 in dose escalation, 10 in expansion). One patient (1 of 22; 4.5%) experienced DLT in cohort 6 (80 KBq/kg) but none in cohort 7; MTD was not reached, and RP2D was the highest dose level (93.3 KBq/kg). The majority of high-grade adverse events (AEs) were hematologic with an apparent relationship with administered radioactivity. Nonhematologic AEs were generally of low grade. Prostate-specific antigen (PSA) declines and circulating tumor cell (CTC) control were observed: 46.9% had at least 50% PSA decline at any time (34.4% confirmed PSA response), and protocol-defined CTC count response occurred in 13 of 22 (59.1%). CONCLUSION To our knowledge, this is the first-in-human phase I dose-escalation trial of a single dose of 225 Ac-J591 in 32 patients with pretreated progressive mCRPC demonstrated safety and preliminary efficacy signals. Further investigation is underway.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
NAN发布了新的文献求助10
刚刚
动听的琴完成签到,获得积分10
刚刚
zs发布了新的文献求助30
刚刚
AM发布了新的文献求助10
刚刚
大栗子发布了新的文献求助10
1秒前
1秒前
Benthesikyme完成签到,获得积分10
2秒前
imcwj完成签到 ,获得积分10
2秒前
青柠空发布了新的文献求助10
3秒前
流星发布了新的文献求助10
4秒前
nic完成签到,获得积分10
4秒前
阿猫发布了新的文献求助10
4秒前
4秒前
1st完成签到 ,获得积分10
5秒前
毛毛发布了新的文献求助10
5秒前
晚风发布了新的文献求助10
7秒前
ZND发布了新的文献求助10
8秒前
8秒前
科目三的应助被蛙蛙采纳,获得10
9秒前
9秒前
Hello的应助被Belle采纳,获得10
10秒前
nikola完成签到,获得积分10
10秒前
领导范儿的应助被AM采纳,获得10
10秒前
小蘑菇的应助被KKZNB采纳,获得10
10秒前
薄荷完成签到 ,获得积分10
10秒前
minmi发布了新的文献求助10
11秒前
11秒前
九七发布了新的文献求助30
13秒前
在水一方的应助被阿猫采纳,获得10
13秒前
秋风的应助被孙朱珠采纳,获得10
13秒前
14秒前
14秒前
wangbw发布了新的文献求助10
14秒前
英姑的应助被AN采纳,获得10
15秒前
Jasper的应助被AN采纳,获得10
15秒前
小马甲的应助被AN采纳,获得80
15秒前
汉堡包的应助被AN采纳,获得10
15秒前
16秒前
简单大西瓜完成签到,获得积分10
17秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178807
求助须知:如何正确求助?哪些是违规求助? 9569558
关于积分的说明 21805222
捐赠科研通 7773974
什么是DOI,文献DOI怎么找? 3432933
关于科研通互助平台的介绍 2556873
邀请新用户注册赠送积分活动 2478593